Arch Therapeutics, Inc.
Company Snapshot: Arch Therapeutics, Inc.
Arch Therapeutics, Inc. is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as AC5 Surgical Hemostatic Device™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures.
- Sep 20 2017 Arch Therapeutics to Provide Corporate Updates at Upcoming Industry and Investment Conferences
- Sep 12 2017 Arch Therapeutics Reports Favorable Results in Repeat Dose Testing of AC5™ for Subchronic Systemic Toxicity
- Sep 6 2017 Arch Therapeutics to Provide Corporate Update at the 19th Annual Rodman & Renshaw Global Investment Conference In New York City September 10-12, 2017
- Jul 25 2017 Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5(TM) Topical Gel